Related Experiment Videos
Fc gamma RI blockade and modulation for immunotherapy
P K Wallace1, T Keler, P M Guyre
1Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, USA. pkw@dartmouth.edu
Cancer Immunology, Immunotherapy : CII
|January 22, 1998
Summary
This study shows that mAb H22 effectively blocks Fc gamma RI-mediated phagocytosis in immune thrombocytopenic purpura (ITP). It also down-modulates Fc gamma RI expression on monocytes, offering a potential new therapeutic strategy for ITP patients.
Area of Science:
- Immunology
- Hematology
Background:
- Immune thrombocytopenic purpura (ITP) is often treated with splenectomy and corticosteroids.
- A subset of ITP patients (10-15%) are refractory to conventional therapies.
- Intravenous immunoglobulin (IVIg) provides transient, life-saving responses in non-responsive ITP patients, potentially via Fc receptor blockade.
Purpose of the Study:
- To investigate the role of individual Fc gamma receptors (Fc gamma R) in ITP.
- To evaluate the efficacy of a humanized monoclonal antibody, mAb H22, targeting Fc gamma RI (CD64).
Main Methods:
- Humanized mAb H22, targeting an epitope on Fc gamma RI outside the ligand-binding domain, was utilized.
- The binding and functional effects of mAb H22 on Fc gamma RI were assessed.
- Fc gamma RI-mediated phagocytosis of opsonized red blood cells was measured.
- Fc gamma RI expression on monocytes was analyzed after cross-linking with mAb H22.
Main Results:
- mAb H22 demonstrated superior blockade of Fc gamma RI-mediated phagocytosis compared to an irrelevant IgG.
- Cross-linking Fc gamma RI with mAb H22 led to rapid down-modulation of Fc gamma RI expression on monocytes within 2 hours.
Conclusions:
- mAb H22 effectively inhibits Fc gamma RI-mediated phagocytosis.
- mAb H22 induces Fc gamma RI down-modulation on monocytes, suggesting a novel therapeutic mechanism for ITP.
- These findings support the potential of mAb H22 as a targeted therapy for refractory ITP.